238 related articles for article (PubMed ID: 12826247)
1. Chemotherapy for advanced pancreatic cancer.
Haller DG
Int J Radiat Oncol Biol Phys; 2003; 56(4 Suppl):16-23. PubMed ID: 12826247
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Kozuch P; Petryk M; Evans A; Bruckner HW
Surg Clin North Am; 2001 Jun; 81(3):683-90. PubMed ID: 11459281
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Heinemann V
Semin Oncol; 2002 Dec; 29(6 Suppl 20):9-16. PubMed ID: 12577228
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for advanced pancreatic cancer.
Chua YJ; Cunningham D
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):327-48. PubMed ID: 16549331
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine: progress in the treatment of pancreatic cancer.
Heinemann V
Oncology; 2001; 60(1):8-18. PubMed ID: 11150902
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based combination treatment of pancreatic cancer.
Heinemann V
Semin Oncol; 2002 Feb; 29(1 Suppl 3):25-35. PubMed ID: 11894005
[TBL] [Abstract][Full Text] [Related]
7. Conventional chemotherapy of advanced pancreatic cancer.
Giuliani F; Di Maio M; Colucci G; Perrone F
Curr Drug Targets; 2012 Jun; 13(6):795-801. PubMed ID: 22458526
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Oh SY; Kim HJ; Kim TH; Lee GW; Kim HG; Jeong CY; Kwon HC; Kang JH
Invest New Drugs; 2010 Jun; 28(3):343-9. PubMed ID: 19444385
[TBL] [Abstract][Full Text] [Related]
9. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
10. [The update on pancreatic cancer chemotherapy].
Brasiūniene B; Juozaityte E; Brasiūnas V; Inciūra A
Medicina (Kaunas); 2003; 39(10):1016-25. PubMed ID: 14578647
[TBL] [Abstract][Full Text] [Related]
11. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel in the management of advanced pancreatic cancer.
Lopes G; Rocha Lima CM
Semin Oncol; 2005 Apr; 32(2 Suppl 4):S10-23. PubMed ID: 16015551
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Lipton A; Campbell-Baird C; Witters L; Harvey H; Ali S
J Clin Gastroenterol; 2010 Apr; 44(4):286-8. PubMed ID: 20216081
[TBL] [Abstract][Full Text] [Related]
14. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Stathopoulos GP; Syrigos K; Aravantinos G; Polyzos A; Papakotoulas P; Fountzilas G; Potamianou A; Ziras N; Boukovinas J; Varthalitis J; Androulakis N; Kotsakis A; Samonis G; Georgoulias V
Br J Cancer; 2006 Sep; 95(5):587-92. PubMed ID: 16909140
[TBL] [Abstract][Full Text] [Related]
16. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
[TBL] [Abstract][Full Text] [Related]
17. New perspectives in the management of pancreas cancer.
Haller DG
Semin Oncol; 2003 Aug; 30(4 Suppl 11):3-10. PubMed ID: 14506598
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W
Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181
[TBL] [Abstract][Full Text] [Related]
19. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]